ARWR Arrowhead Pharmaceuticals, Inc.

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Goldman sees biotech’s recent gains holding up despite macro pressures, supported by deal activity, clinical progress, and a more favorable regulatory backdrop.

Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after reporting interim Phase 1/2a data for ARO-DIMER-PA, its dual RNA interference candidate targeting atherosclerotic cardiovascular disease due to mixed hyperlipidemia. Arrowhead Pharmaceuticals has been volatile around the interim ARO-DIMER-PA update, with the share price down 19.76% over the past week and 25.65% over the past month. However, the 1 year total shareholder return of 116.62% and 3 year total shareholder return of...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Early Dimer Data

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disord

Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Tuesday shared interim topline clinical data from a Phase 1/2a trial. The trial is evaluating ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. Hyperlipidemia is defined by an excess of fats, or lipids—such as cholesterol and triglycerides—in the blood. Read Also: Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat Interim ARO-

ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

Perry's liquidity event comes as the Arrowhead stock price surged.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) presented detailed results from the randomized, double-blind, placebo-controlled Phase 3 SHASTA-3 and SHASTA-4 studies in 757 adults with severe hypertriglyceridemia. Four quarterly 25-mg doses of plozasiran produced median triglyceride reductions of 79% and 81% at Month 12, compared with approximately 27% for placebo in each study. A prespecified pooled analysis showed […]

Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.

Arrowhead Pharmaceuticals (ARWR) attracted fresh attention after presenting pivotal Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026. The company highlighted triglyceride reductions and fewer acute pancreatitis events in severe hypertriglyceridemia. Arrowhead Pharmaceuticals has seen its share price give back some ground in the past week, with the 1-day share price return down 2.97% and the 7-day share price return down 5%. At the same time, the 90-day share price...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The company said the data

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reached a major European milestone on August 17 when it announced the availability of REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany. Following European Commission authorization in June 2026, the drug is now listed in the Lauer-Taxe database for prescribing and reimbursement. Unlike existing options requiring genetic confirmation, REDEMPLO […]

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Arrowhead Pharmaceuticals Inc (ARWR) reports robust clinical progress and commercial growth, despite a wider net loss in Q3 2026.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlighting continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome (

Arrowhead Pharmaceuticals recently reported that its siRNA drug plozasiran met all primary and key secondary endpoints in two global Phase 3 trials for severe hypertriglyceridemia, while also completing patient enrollment for the YOSEMITE Phase 3 trial of zodasiran in the ultra-rare condition homozygous familial hypercholesterolemia. Together, these late-stage milestones highlight Arrowhead’s push to expand its RNAi portfolio into high-need cardiometabolic diseases, potentially broadening...

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.

Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and keeps a Buy rating on the shares.

Shares of Arrowhead Pharmaceuticals jumped 19% Wednesday after the company said its experimental drug, called plozasiran, sharply cut levels of triglycerides, a type of fat in the blood, in two late-stage trials aimed at patients with dangerously high levels of the fat. Plozasiran, given as a shot every three months, lowered triglycerides by as much as 81% after a year, compared with a drop of about 27% for patients on placebo. Arrowhead said it planned to ask the Food and Drug Administration by year-end to approve it for the larger population of patients with severe high triglycerides.

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) skyrocketed to a five-year high on Wednesday, as investors began positioning portfolios ahead of the supplemental new drug application (sNDA) of its drug candidate, plozasiran, for the treatment of severe hypertriglyceridemia. In intra-day trading, the stock soared by as much as 28 percent to a record high of $95.49—a level it […]

Arrowhead Pharmaceuticals (ARWR) said Wednesday topline results from its global phase 3 clinical stu

The biotech firm reported positive topline results from two Phase 3 studies evaluating its hypertriglyceridemia therapy.

Late-stage studies achieve all primary and secondary goalsArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares jumped 18% on Wednesday after the company announced positive topline data from its Phase 3 SHASTA-3 and SHASTA-4 clinical trials evaluating plozasiran in patients with severe hypertriglyceridemia.

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

After a sharp 398.1% gain over the past year, Arrowhead Pharmaceuticals no longer looks obviously cheap, with its current valuation checks pointing to a more balanced picture rather than a clear bargain or clear excess. Arrowhead Pharmaceuticals' share price return of 398.1% over one year is extreme for a biotech stock and raises the bar for what needs to happen next to justify the move. The recent European Commission authorisation for Redemplo can support higher revenue expectations over...

EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.

Iran fired on ships, Trump answered with missiles and seized the Strait of Hormuz, and Wall Street spent Tuesday sorting out who gets hurt and who benefits. Analysts at KeyBanc, HSBC, and Mizuho made some bold calls you may not see coming.